Navigation Links
Rafarma Pharmaceuticals, Inc. Achieves Full Certification
Date:12/18/2012

Sandy, UT (PRWEB) December 17, 2012

Rafarma Pharmaceuticals, Inc. (the ”Company”) OTC symbol “APKND” announced that its manufacturing and packaging facility in Lipetsk, Russia was fully licensed last November 9th and exhibited by GMP (“Good Manufacturing Practices”) Certificate # 109489 7000-430 (see: http://rafarma.com).

The facility is ISO 9001 and IHC Q 10 compliant. These internationally recognized certifications allow sales and distribution of all permitted products throughout Europe and all nations that are a party to the above standards. The manufacturing facility is currently operating at 30% capacity during its “start-up” phase, and is expected to reach full production during the second quarter of 2013.

With the resignation of Vladimir Bondar as Director and President and Natalia Leonidovna Stupina as Director and CFO due to other commitments, the Company appointed Mr. Sergey Brusnitsin as its new Director and CFO. Mr. Brusnitsin earned his PhD in Economics from the Moscow Institute of Economics and was formerly the director of the Federal Revenue Service of Russia. He has been affiliated with the Company in several capacities throughout its development phase. Mr. Alexander Ageev continues to function as Director, Secretary/Treasurer and Mr. David Anderson will remain as Director and CEO and perform the function of President until the first annual meeting, now scheduled for March 1, 2013.

With expended development costs in excess of $200 million, and expected first year revenue expectations exceeding $100 million, and an excellent product portfolio, the Company is expected to be a leading supplier of pharmaceuticals in the years to come.

The new OTC trading symbol for the Company will be announced by FINRA on January 2, 2013 and be effective January 3, 2013.

Safe Harbor Statement
Matters discussed in this
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
2. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
6. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
9. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 WriteResult, LLC ... – has been working with a team of researchers ... Haven Farms Community Farming Collaborative to provide electronic questionnaire ... The study, which started in May, aims to ... provides participants weekly exposure to and participation in urban ...
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for its Oral Amphotericin B program.  The company ... vitro work involving samples from HIV/AIDS patients ... complete pre clinical studies and regulatory filings to ... trial, utilizing approximately $700,000 of funding and technological ...
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
Breaking Biology Technology:myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... Md., May 20 Martek Biosciences Corporation (Nasdaq: ... of its second quarter of fiscal 2009 on June 3, ... the release, at 4:45 p.m. ET Martek will conduct a ... interested parties may listen to the call live via webcast ...
... Launch into High Growth Brazilian Market for Aesthetic ... announced today the receipt of ANVISA clearance to ... in Brazil. ANVISA (Agencia Nacional de Vigilancia ... regulatory agency charged with clearing all applications to ...
... Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") is pleased to ... year and guidance on its projected financial performance for the ... , In Q1 2009, ... $0.68 million), representing a 127 percent increase year-over-year from the ...
Cached Biology Technology:Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 2Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 3Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 2Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 3
(Date:10/18/2014)... of 2,000 patients referred for evaluation of suspected ... diagnosis for 25 percent, including detection of a ... contributing to disease, according to a study appearing ... released to coincide with the American Society of ... the exons or coding regions of thousands of ...
(Date:10/17/2014)... . Why do ... to reproduce? And why are there two sexes anyway? These ... of the research journal Molecular Human Reproduction published ... Bielefeld University Bielefeld has compiled this special issue on sperm ... to copulate with several males in quick succession – chimpanzees ...
(Date:10/16/2014)... wages war on the human body. Battles are ... In pancreatic cancer, this stalemate—known as tumor dormancy—can ... malignant, a phenomena that is poorly understood. ... laboratory of Salvatore Torquato, a Professor of Chemistry ... surrounding tumor dormancy and the switch to a ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... CHAMPAIGN, Ill. Up to 4 percent of the methane ... have been unable to identify the source of this potent ... culprit: a bit of "weird chemistry" practiced by the most ... the journal Science . The researchers who made ...
... blanket of snow in the winter can help boost ... is one way to ensure that blanket coverage, according ... Agricultural Research Service (ARS) soil scientist David Huggins conducted ... accumulation and soil water levels across entire fields. ARS ...
... NY) Researchers at Albert Einstein College of Medicine ... mechanism that the immune system uses to respond to infection. ... lead to new strategies for boosting effectiveness of all vaccines. ... journal Immunity . Grgoire Lauvau, Ph.D.One way the ...
Cached Biology News:Study identifies prime source of ocean methane 2Study identifies prime source of ocean methane 3No-till farming helps capture snow and soil water 2Early activation of immune response could lead to better vaccines 2
Use our experts and resources to develop reagent systems for your applications....
Request Info...
Ultra-sensitive, non-radioactive detection of Protein G. Measure Protein G levels quickly and easily....
IC50: 190 pg/ml · Limit of detection: 60 pg/ml...
Biology Products: